Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

$4.8bn MBO Japan's Largest

Executive Summary

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

You may also be interested in...



Taisho Boosted By Overseas Sales With Japanese Business Flat

Taisho's Self-Medication business posted a solid gain in the six months ended 30 September as a recovery in its Overseas operation boosted a flat performance in Japan.

Japan's Taisho Counts On Overseas Sales As Domestic Business Struggles During COVID-19

Strength in its overseas consumer health business, particularly in Asia, helped Taisho offset falling sales at home due to the impact of the COVID-19 pandemic in its latest nine-month reporting period.

Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC

TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel